These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19202599)

  • 21. Diphenylpyrroles: Novel p53 activators.
    Gomha SM; Eldebss TM; Abdulla MM; Mayhoub AS
    Eur J Med Chem; 2014 Jul; 82():472-9. PubMed ID: 24934571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
    Ghosh M; Huang K; Berberich SJ
    Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Abnormal p53-HDM2 interaction in hematological malignancy].
    Tabe Y; Kojima K
    Nihon Rinsho; 2014 Jun; 72(6):1042-6. PubMed ID: 25016801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allosteric Interactions by p53 mRNA Govern HDM2 E3 Ubiquitin Ligase Specificity under Different Conditions.
    Medina-Medina I; García-Beltrán P; de la Mora-de la Mora I; Oria-Hernández J; Millot G; Fahraeus R; Reyes-Vivas H; Sampedro JG; Olivares-Illana V
    Mol Cell Biol; 2016 Aug; 36(16):2195-205. PubMed ID: 27215386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting Hdm2 and Hdm4 in Anticancer Drug Discovery: Implications for Checkpoint Inhibitor Immunotherapy.
    Ntwasa M
    Cells; 2024 Jun; 13(13):. PubMed ID: 38994976
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rationally Designed Polypharmacology: α-Helix Mimetics as Dual Inhibitors of the Oncoproteins Mcl-1 and HDM2.
    Conlon IL; Drennen B; Lanning ME; Hughes S; Rothhaas R; Wilder PT; MacKerell AD; Fletcher S
    ChemMedChem; 2020 Sep; 15(18):1691-1698. PubMed ID: 32583936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.
    Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
    Oncotarget; 2015 Feb; 6(5):2623-40. PubMed ID: 25739118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MDM2 inhibitors for pancreatic cancer therapy.
    Azmi AS; Philip PA; Almhanna K; Beck FW; Sarkar FH; Mohammad RM
    Mini Rev Med Chem; 2010 Jun; 10(6):518-26. PubMed ID: 20377522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of cancer-related pathways by protein NEDDylation and strategies for the use of NEDD8 inhibitors in the clinic.
    Abidi N; Xirodimas DP
    Endocr Relat Cancer; 2015 Feb; 22(1):T55-70. PubMed ID: 25504797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53.
    Linares LK; Hengstermann A; Ciechanover A; Müller S; Scheffner M
    Proc Natl Acad Sci U S A; 2003 Oct; 100(21):12009-14. PubMed ID: 14507994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy.
    Devine T; Dai MS
    Curr Pharm Des; 2013; 19(18):3248-62. PubMed ID: 23151129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Study on natural products for drug development].
    Tsukamoto S
    Yakugaku Zasshi; 2010 Oct; 130(10):1273-81. PubMed ID: 20930478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HDM2 and HDMX Proteins in Human Cancer.
    Hároníková L; Vojtěšek B
    Klin Onkol; 2018; 31(Suppl 2):63-70. PubMed ID: 31023026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natural product MDM2 inhibitors: anticancer activity and mechanisms of action.
    Qin JJ; Nag S; Voruganti S; Wang W; Zhang R
    Curr Med Chem; 2012; 19(33):5705-25. PubMed ID: 22830335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure.
    Zhao J; Wang M; Chen J; Luo A; Wang X; Wu M; Yin D; Liu Z
    Cancer Lett; 2002 Sep; 183(1):69-77. PubMed ID: 12049816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Small-molecule inhibitors of the p53-MDM2 interaction.
    Vu BT; Vassilev L
    Curr Top Microbiol Immunol; 2011; 348():151-72. PubMed ID: 21046355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3.
    Patton JT; Mayo LD; Singhi AD; Gudkov AV; Stark GR; Jackson MW
    Cancer Res; 2006 Mar; 66(6):3169-76. PubMed ID: 16540668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibitors of MDM2 and MDMX: a structural perspective.
    Riedinger C; McDonnell JM
    Future Med Chem; 2009 Sep; 1(6):1075-94. PubMed ID: 21425995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of a natural product inhibitor targeting protein neddylation by structure-based virtual screening.
    Zhong HJ; Ma VP; Cheng Z; Chan DS; He HZ; Leung KH; Ma DL; Leung CH
    Biochimie; 2012 Nov; 94(11):2457-60. PubMed ID: 22709868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment.
    Gupta A; Shah K; Oza MJ; Behl T
    Biomed Pharmacother; 2019 Jan; 109():484-492. PubMed ID: 30551517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.